Dillon & Associates Inc. Decreases Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Dillon & Associates Inc. lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 63.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,897 shares of the biopharmaceutical company’s stock after selling 8,447 shares during the period. Dillon & Associates Inc.’s holdings in Regeneron Pharmaceuticals were worth $2,752,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the stock. Dodge & Cox grew its holdings in shares of Regeneron Pharmaceuticals by 64.6% during the second quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock valued at $2,008,799,000 after buying an additional 1,502,198 shares during the last quarter. Norges Bank acquired a new stake in Regeneron Pharmaceuticals during the second quarter valued at $628,151,000. Acadian Asset Management LLC increased its stake in shares of Regeneron Pharmaceuticals by 234.7% in the 2nd quarter. Acadian Asset Management LLC now owns 465,740 shares of the biopharmaceutical company’s stock valued at $244,480,000 after purchasing an additional 326,583 shares in the last quarter. Loomis Sayles & Co. L P raised its stake in shares of Regeneron Pharmaceuticals by 18.6% during the 2nd quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock worth $1,019,062,000 after buying an additional 305,089 shares during the period. Finally, Invesco Ltd. lifted its holdings in Regeneron Pharmaceuticals by 26.5% during the second quarter. Invesco Ltd. now owns 1,075,824 shares of the biopharmaceutical company’s stock valued at $564,808,000 after purchasing an additional 225,078 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

REGN has been the subject of several research reports. BMO Capital Markets boosted their price target on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an “outperform” rating in a research report on Thursday, December 4th. Canaccord Genuity Group upped their price objective on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a “buy” rating in a report on Thursday, December 4th. Citigroup lifted their price target on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Hsbc Global Res upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 24th. Finally, Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, January 10th. Four equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $791.05.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the transaction, the vice president directly owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. The trade was a 9.24% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the transaction, the director owned 2,352 shares in the company, valued at approximately $1,538,843.04. This trade represents a 73.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 8,431 shares of company stock worth $5,733,521 in the last three months. Insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $741.92 on Friday. The firm has a fifty day moving average price of $747.36 and a 200 day moving average price of $634.57. The stock has a market cap of $77.98 billion, a PE ratio of 17.77, a price-to-earnings-growth ratio of 1.97 and a beta of 0.39. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company had revenue of $3.75 billion during the quarter, compared to analysts’ expectations of $3.57 billion. During the same quarter in the previous year, the business earned $12.46 earnings per share. The firm’s revenue for the quarter was up .9% on a year-over-year basis. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Shareholders of record on Thursday, November 20th were given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend was Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.43%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.